HCR 579 Module 2 Evaluating a Translational Study Example

Course	HCR 579 Translational Research in Drug Discovery and Development
Module	Module 2
Paper type	Translational study evaluation
Length	About 650 words, 5 pages
Format	APA 7 student paper
School	Arizona State University
Program	MS in Regulatory Science
Updated	October 2026

Free sample paper for HCR 579 Module 2

From a Rare Gene Variant to a Drug: Evaluating the First-in-Human Trials of a PCSK9 Antibody

Student Name

MS in Regulatory Science, Arizona State University

HCR 579: Translational Research in Drug Discovery and Development

Instructor Name

Month Day, Year

What this page is doingThe title traces the translation the paper evaluates, from genetic discovery to clinical testing.

From a Rare Gene Variant to a Drug: Evaluating the First-in-Human Trials of a PCSK9 Antibody

Introduction

Translational research carries discoveries across stages: from basic science to human studies, from human studies to clinical practice and from practice to population health. Many promising discoveries stall between stages. The development of PCSK9 inhibitors is a rare example of fast, successful translation, and the first-in-human trials of alirocumab sit at its center. This paper evaluates those trials and their place on the continuum.

The Discovery: A Natural Experiment

The target came from human genetics rather than animal models. In the Atherosclerosis Risk in Communities study, Black participants who carried nonsense mutations in the PCSK9 gene had 28% lower LDL cholesterol and an 88% lower risk of coronary heart disease over 15 years; in white participants, a different variant lowered LDL by 15% and risk by 47% (Cohen et al., 2006). Because these people had carried the variants since birth, the study acted as a natural experiment showing that lifelong lower PCSK9 activity was both safe and protective. That finding made PCSK9 an unusually well-validated target before any drug existed.

What this page is doingStarting with the genetic study explains why the later trials could move quickly: the target had been validated in people, not only in mice.

The Translational Study: First-in-Human Trials

Stein et al. (2012) reported three Phase 1 trials of REGN727, later named alirocumab. Two single ascending-dose studies in healthy volunteers, one intravenous with 40 participants and one subcutaneous with 32, were followed by a multiple-dose study in 61 adults with high cholesterol, most of them already taking atorvastatin. The primary outcome was adverse events; the main secondary outcome was the effect on lipids. There were no discontinuations for adverse events, and in the statin-treated patients, doses of 50, 100 and 150 mg lowered LDL cholesterol by 39, 54 and 61 percentage points more than placebo.

Evaluation

Strengths

The trials were randomized and placebo-controlled even at Phase 1, which made the lipid effects interpretable. They tested the drug both alone in healthy volunteers and on top of a statin in the patients who would use it, so they addressed the key question of additive benefit early. The LDL reductions were large, dose-related and consistent with the mechanism, providing proof of mechanism in humans.

Limitations

Phase 1 trials are small and short. Safety findings over a few weeks in about 130 people cannot detect rare or delayed harms, and an antibody given for decades might provoke immune responses or unexpected effects. LDL cholesterol is a surrogate endpoint; the trials could not show fewer heart attacks or deaths. Finally, the sponsors funded and conducted the trials, which is typical for Phase 1 but makes independent replication important.

Completing the Translation

The surrogate gap was closed later. In ODYSSEY OUTCOMES, 18,924 patients with a recent acute coronary syndrome on intensive statin therapy were randomized to alirocumab or placebo; the primary composite of cardiovascular events occurred in 9.5% against 11.1%, a 15% relative reduction (Schwartz et al., 2018). The arc from genetic discovery in 2006 to outcomes evidence in 2018 took about twelve years.

Translational stage	Study	What it showed
Discovery and target validation	Cohen et al., 2006	Lifelong low PCSK9 activity lowers LDL and heart disease
First in human	Stein et al., 2012	Safe in the short term; large, dose-related LDL lowering
Clinical outcomes	Schwartz et al., 2018	Fewer cardiovascular events after acute coronary syndrome

Why This Translation Worked

Three features explain the speed. The target was validated in humans, not inferred from animals. The biomarker, LDL cholesterol, was well established, so early trials could measure the drug's effect precisely. And the clinical endpoint was common enough that an outcomes trial could be completed within a few years.

Conclusion

The first-in-human trials of alirocumab were well designed for their purpose: to show safety and proof of mechanism quickly. Their limits were the limits of any Phase 1 study, and the later outcomes trial addressed the most important one. The case shows that the strongest translational programs begin with evidence in people.

References

Cohen, J. C., Boerwinkle, E., Mosley, T. H., Jr., & Hobbs, H. H. (2006). Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New England Journal of Medicine, 354(12), 1264-1272. https://doi.org/10.1056/NEJMoa054013

Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., . . . Zeiher, A. M. (2018). Alirocumab and cardiovascular outcomes after acute coronary syndrome. New England Journal of Medicine, 379(22), 2097-2107. https://doi.org/10.1056/NEJMoa1801174

Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., Du, Y., Kranz, T., Gasparino, E., & Swergold, G. D. (2012). Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. New England Journal of Medicine, 366(12), 1108-1118. https://doi.org/10.1056/NEJMoa1105803

HCR 579 Module 2 instructions, in plain terms

Written Assignment 1 is worth 100 points, the largest of HCR 579's written assignments, and it is due in Module 2, the module on the translational process and the translational drug development continuum. The syllabus lists the evaluation of a translational study among the course's papers, with full instructions and rubric in Canvas. Pick a study that sits clearly at one point on the continuum, often the first-in-human step where basic science meets clinical testing, and judge it in context: the discovery behind it, its design and findings, the weight of its evidence and the research it made necessary. The course text, Shah and Wells's Translational Research in Drug Discovery and Development, frames the stages of translation, which gives your evaluation its vocabulary. Choose a study with a full published report so you can judge its design rather than its press coverage.

Inside the HCR 579 Module 2 example

The sample opens by defining translation and naming the case. A discovery section explains the genetic study that validated the target, with its numbers. The translational study itself is then described: design, participants, outcomes and results. The evaluation is split into strengths and limitations, each tied to features of the trials. A section on completing the translation reports the outcomes trial that answered the main limitation, and a table places the three studies on the continuum. A short section explains why this translation was fast, and the conclusion states the lesson for translational programs. The study's numbers are reported once, precisely, and then interpreted, which keeps the evaluation readable.

Where the marks sit in the HCR 579 Module 2 rubric

Written Assignment 1 carries 100 points. An evaluation scores well when it places the study correctly on the translational continuum, describes its design and results accurately, judges strengths and limitations with specific reasons, explains how the study connects to earlier discovery and later clinical evidence and writes clearly with correct citations. Marks drop for papers that retell the abstract instead of judging it, when the study's stage is misidentified, when limitations are generic and when the broader translational story is missing. Readers value attention to surrogate endpoints and early safety limits, since those are the central weaknesses of most first-in-human studies.

HCR 579 Module 2 help from the desk

Choose a study with a clear before and after: the discovery that motivated it and the evidence that followed. Read the full methods. Say which stage of translation the study represents. Separate strengths and limitations and give a reason for each. Show what later research resolved. A table of the stages helps. Avoid relying on news summaries. Still choosing a study? Ask the desk for ones whose path from lab to clinic is well recorded. Explain any jargon, such as proof of mechanism, the first time it appears. Distinguish what the study showed from what later studies showed, so credit goes where it belongs. Keep the paper focused on one translational path rather than the whole field.

Write yours, or have the desk draft it

This paper is an original model document written by our desk, not a submitted student paper and not an official Arizona State University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.

More HCR 579 and MS in Regulatory Science sample papers

HCR 579 Module 2 questions, answered

Where can I find a free HCR 579 Module 2 sample paper?

This page has a full HCR 579 Written Assignment 1 sample evaluating the first-in-human trials of a PCSK9 antibody.

What is the translational continuum?

The path that carries a discovery from basic science into human studies, clinical practice and population health.

Why are first-in-human trials important in translational research?

They show whether a drug acts on its target safely in people, linking laboratory discovery to clinical development.

How did PCSK9 become a drug target?

People born with PCSK9 variants had lower LDL cholesterol and far less heart disease, validating the target in humans.

Which textbook does HCR 579 use?

Shah and Wells's Translational Research in Drug Discovery and Development, a Top Hat interactive text.

HCR 579 Module 2 Written Assignment 1: Evaluating a Translational Study Example